Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 99,700 shares, an increase of 62.1% from the May 31st total of 61,500 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 100,700 shares, the short-interest ratio is presently 1.0 days.

Chemomab Therapeutics Stock Performance

Shares of Chemomab Therapeutics stock traded down $0.06 during trading on Friday, hitting $0.91. 69,212 shares of the stock traded hands, compared to its average volume of 168,781. The company has a fifty day moving average price of $0.90 and a two-hundred day moving average price of $0.73. Chemomab Therapeutics has a twelve month low of $0.42 and a twelve month high of $1.50. The stock has a market cap of $10.08 million, a P/E ratio of -0.57 and a beta of 0.48.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). On average, equities research analysts expect that Chemomab Therapeutics will post -0.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CMMB has been the subject of several research analyst reports. Maxim Group raised Chemomab Therapeutics to a “strong-buy” rating in a research note on Friday, May 24th. Oppenheimer upgraded shares of Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research note on Monday, May 6th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).